Sorry, you need to enable JavaScript to visit this website.

Skip to main content

Search

Meet Our Immunology Leadership Team

Leaders in Immunology

 

Immunology

Immunology

Skin cells 20x magnification
Skin cells at 20x magnification

Sue Dillon, Ph.D. has end-to-end responsibility for immunology drug discovery, biomarkers, translational medicine, clinical development and life cycle management for a number of industry-leading products. She leads a global team focused on combining internal and external innovation approaches to discover and develop new solutions for patients with serious autoimmune diseases. Sue is also responsible for management of the Janssen Human Microbiome Institute, Covagen LLC and Janssen Immunosciences. 

An experienced leader in R&D, Sue has held senior positions at large pharmaceutical companies and biotechs. Sue joined the Johnson & Johnson Family of Companies as Vice President, Centocor R&D Discovery Research in 2001 and has held positions of increasing responsibility leading to her 2009 appointment to her current role as Global Therapeutic Area Head for Immunology. During her tenure, the Immunology Therapeutic Area has continued to build a strong immunology portfolio and pipeline of innovative assets in early development and discovery. 

Sue earned her Ph.D. in Microbiology and Immunology from Thomas Jefferson University, Philadelphia, Pennsylvania. She completed a National Institutes of Health (NIH)-sponsored postdoctoral fellowship in Immunology at Duke University, has published more than 50 scientific articles, and is inventor on three issued patents. In 2007, Sue was awarded the Distinguished Alumni Award from Thomas Jefferson University, and in 2013 Sue was selected by FierceBiotech as one of the “Top Women in Biotech”. Sue has served on the Board of Trustees of Bryn Mawr Hospital, and is currently on the Board of The Wistar Institute in Philadelphia.

Susan B. Dillon, Ph.D.

Global Therapeutic Area Head, Immunology, Janssen Research & Development

Teri Lawver is the Global Commercial Strategy Leader, Global Vice President, for the Immunology Therapeutic Area with Janssen Pharmaceutical Companies of Johnson & Johnson. In this role, Teri has end-to-end responsibility for the Janssen Immunology portfolio and pipeline.

Teri has more than 20 years of global healthcare and business leadership experience spanning three continents, three healthcare sectors, and dozens of disease areas. She has a proven track record in building new businesses, delivering sustainable, innovation-based growth, and developing high-performance teams.

Teri joined Johnson & Johnson at Centocor in 2002. During her 5 years at Centocor she advanced through leadership positions in Marketing, Sales, and Strategic Accounts Management, and was responsible for launching and leading the first Remicade Gastroenterology Marketing and Sales Teams.

From 2007 through 2013 Teri progressed through General Management positions in our Medical Device Sector, and in 2011 was appointed President of Johnson & Johnson Medical Device Companies in Canada. In 2013 Teri was appointed Global Commercial Strategy Leader, Global Vice President for the Janssen Cardiovascular & Metabolism Therapeutic Area.

Before joining Johnson & Johnson, Teri was an Associate Principal with McKinsey & Company in the Firm’s New Jersey, Atlanta, and Sao Paolo, Brazil offices and was a leader in the Firm’s Global Healthcare Practice. She began her career as a Derivatives Analyst with Bloomberg Financial Markets, LLP.

She holds a Bachelor of Science degree, summa cum laude, from Georgetown University, and a Master of Business Administration from Duke University.

Active with community and philanthropic causes, Teri serves on the Advisory Council of the NetsforLife® Partnership for Malaria Prevention in Africa, and on the Advancement Committee for Episcopal Relief & Development, where she champions promoting health and fighting disease among the world’s most under-served populations. She was recently named to the NJBiz “Best 50 Women in Business” list for 2016.

Teri L. Lawver

Global Commercial Leader Global Vice President, Immunology Janssen Research & Development

With nearly 25 years of experience in the pharmaceutical and biotechnology industry, Ian Anderson, Ph.D. leads immunology discovery and collaboration efforts globally in partnership with the Johnson & Johnson Innovation Centers. In this role, Ian applies the highest level of scientific expertise and insights to identify the best opportunities for value-generating collaborations and, in developing an industry-leading portfolio of investments, cultivates a strong scientific reputation and network of experts around the world.

Ian Anderson, Ph.D.

Vice President, Immunology Discovery & Scientific Innovation, Janssen Research & Development

Mark Cunningham is responsible for strategic and operational activities across the Immunology Therapeutic Area. This includes optimizing internal business practices, managing the execution of external science and enabling decisions at the portfolio level. Since joining the Janssen Pharmaceutical Companies of Johnson & Johnson through Centocor Research & Development in 2001, Mark has leveraged years of experience in scientific research, business planning and project management to drive excellence in drug discovery and development by embracing technology and supporting collaboration without boundaries.

Mark Cunningham

Head, Strategy & Business Planning, Immunology, Janssen Research & Development

As Head of Immunology Development, Newman Yeilding, M.D. provides scientific and management leadership of development initiatives and investments globally, directing and overseeing all programs supporting new molecular entities within the rheumatoid arthritis, inflammatory bowel disease and psoriasis disease area portfolios, and life cycle indications for the industry-leading Janssen immunology portfolio. Newman joined the Janssen Pharmaceutical Companies of Johnson & Johnson through Centocor in 2002, and was instrumental in the development and approval of one of the company’s leading biologics, which he has continued to oversee through new indications in dermatology and gastroenterology.

Newman Yeilding, M.D.

Head of Development, Immunology, Janssen Research & Development

Dan Baker, M.D. joined the Janssen Pharmaceutical Companies of Johnson & Johnson through Centocor Research & Development in 2000 following an 18-year academic career at the University of Pennsylvania in Philadelphia, Pennsylvania. Since joining Janssen, he has held participation and leadership roles in the clinical development of the industry-leading Janssen immunology portfolio for a plethora of indications, as well as other earlier development assets. As Disease Area Stronghold Leader for Rheumatoid Arthritis (RA), Dan is responsible for leading a cross-functional team of experts to outline near- and long-term, prioritized scientific and business strategies with the goal of maintaining industry leadership in RA.

Dan Baker, M.D.

Disease Area Stronghold Leader, Rheumatoid Arthritis, Janssen Research & Development

Scott Plevy, M.D. is a distinguished, board-certified gastroenterologist who comes to Janssen after a successful career in academia. He has been the lead investigator on multiple early-phase clinical trials and has performed translational research to advance the understanding of novel immunologic interventions. In addition, Scott has contributed to more than 80 peer-reviewed publications concentrating on inflammatory bowel disease (IBD). As IBD Disease Area Stronghold Leader, Scott is responsible for outlining strategies to advance new paradigms for treatment and intervention, collaborating with several internal groups to identify priority targets for drug discovery and development that will enhance the current IBD portfolio.

Scott Plevy, M.D.

Disease Area Stronghold Leader, Inflammatory Bowel Disease, Janssen Research & Development

Anne Fourie, Ph.D., has held several positions of increasing responsibility during her more than 20-year career at the Janssen Pharmaceutical Companies of Johnson & Johnson. In her current role, Anne is responsible for driving the strategic direction of the Psoriasis Disease Area Stronghold, maximizing and progressing the current portfolio, and executing new approaches for disease interception. She also offers extensive oral drug discovery expertise in immunology, as well as diverse experience in leading projects from target discovery through early development.

Anne Fourie, Ph.D.

DISEASE AREA STRONGHOLD LEADER, PSORIASIS, JANSSEN RESEARCH & DEVELOPMENT

Irene Hsu, MBA is responsible for developing and executing the end-to-end strategy for the Rheumatoid Arthritis and Psoriasis Disease Area Strongholds. In this role, she leads a team of global marketing leaders, strategic marketing directors and business and analytics professionals to deliver insights that inform development and commercialization activities. Irene also provides leadership to global commercial teams to ensure effective partnership with cross-functional stakeholders and to implement fully integrated commercial plans that maximize the value of the industry-leading Janssen Immunology portfolio and current pipeline of new therapies.

Irene Hsu, MBA

Disease Area Commercial Leader, Rheumatoid Arthritis & Psoriasis, Janssen Global Services

Sean Larkin, MBA is responsible for developing and executing the end-to-end strategy for the Disease Area Stronghold focused on inflammatory bowel disease. In this role, he leads all new product commercialization activities, portfolio evaluations, business development strategies and opportunity assessments. With nearly 20 years of experience in pharmaceutical marketing, sales, market analytics and new product development, Sean brings a unique perspective as he partners with regional leadership to build innovative commercialization plans that maximize the value of the industry-leading Janssen Immunology portfolio and current pipeline of new therapies. 

Sean Larkin, MBA

Disease Area Commercial Leader, Inflammatory Bowel Disease, Janssen Global Services

Mark Curran, Ph.D. is responsible for delivering the biomarker strategy, integrated patient solutions, big data analysis and development of companion diagnostics for the Immunology Therapeutic Area. His team works to incorporate emerging science and human genetics into new programs with the goal of creating personalized treatment approaches that are predictive of response. Mark’s deep scientific expertise, entrepreneurial passion and commitment to people development continues to strengthen Janssen Immunology leadership in this evolving area of focus.  

Mark Curran, Ph.D.

Vice President, Systems Pharmacology & Biomarkers, Janssen Research & Development

As a member of the Johnson & Johnson organization for more than 20 years, Mike Grissinger, MBA is accountable for the business development activities of the Immunology Therapeutic Area. He offers extensive experience in deals, finance, marketing and business development spanning the consumer, healthcare services and pharmaceutical sectors, as well as a background in chemistry, that enrich his keen decision-making skills. Mike is focused on delivering future growth through the licensing of new products and technologies, and the creation of collaborative relationships with business partners.

Michael Grissinger, MBA

Vice President, Immunology Business Development, Janssen Business Development

As the driver of immunology-focused collaborations out of Johnson & Johnson Innovation, Boston,  Michael Elliott, M.B.B.S., Ph.D., F.R.A.C.P. taps into a long-established network of relationships in the Boston area to identify novel and exciting areas of research to pursue. In this role, Michael applies the highest-level scientific expertise and insights to identify the best opportunities for value-generating collaborations, and in developing an industry-leading portfolio of investments, while cultivating a strong scientific reputation and a network of experts in the Boston and broader Northeastern United States innovation community.

Michael Elliott, M.B.B.S., Ph.D., F.R.A.C.P.

Global Head of Immunology Discovery & Scientific Innovation, Janssen Research & Development

Jackie Benson, Ph.D. leads immunology-focused collaborations out of the Johnson & Johnson Innovation Center located in California. Jackie is responsible for identifying the best external innovation opportunities and value-generating partnerships to further develop the organization’s industry-leading portfolio of Immunology investments. In this role, she works to advance the Immunology Therapeutic Area strategy while building a strong scientific reputation and network of experts in California and the broader Western United States innovation community. 

Jacqueline Benson, Ph.D.

Vice President, Immunology Scientific Innovation, Johnson & Johnson Innovation, California

Biao Zheng, Ph.D., M.D. leads immunology-focused collaborations out of the Johnson & Johnson Innovation Center located in Shanghai, China. Biao is responsible for identifying the best external innovation opportunities and value-generating partnerships to further develop the organization’s industry-leading portfolio of Immunology investments. In this role, he works to advance the Immunology Therapeutic Area strategy while building a strong scientific reputation and network of experts across the Asia Pacific innovation community. 

Biao Zheng, Ph.D., M.D.

Vice President, Immunology Scientific Innovation, Johnson & Johnson Innovation, Asia Pacific

Louise Jopling, Ph.D. leads immunology-focused collaborations out of the Johnson & Johnson Innovation Center located in London. Louise is responsible for identifying the best external innovation opportunities and value-generating partnerships to further develop the organization’s industry-leading portfolio of Immunology investments. In this role, she works to advance the Immunology Therapeutic Area strategy while building a strong scientific reputation and network of experts in London and the broader European innovation community. 

Louise Jopling, Ph.D.

Senior Director, Immunology Scientific Innovation, Johnson & Johnson Innovation, London